{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T09:33:03Z","timestamp":1793007183043,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.critrevonc.2026.105661","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:17:59Z","timestamp":1792595879000},"page":"105661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Antibody\u2013drug conjugates after EGFR-TKI resistance in EGFR-mutant NSCLC: Evidence boundaries, post-progression reassessment, and therapeutic sequencing"],"prefix":"10.1016","volume":"228","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5720-9839","authenticated-orcid":false,"given":"Linlin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renxiang","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105661_bib1","doi-asserted-by":"crossref","first-page":"TPS3156","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS3156","article-title":"EGRET: a first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors","volume":"41","author":"Aggarwal","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib2","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.jtho.2025.06.002","article-title":"A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC","volume":"20","author":"Ahn","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib3","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study","volume":"43","author":"Ahn","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41698-024-00582-1","article-title":"Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis","volume":"8","author":"Azad","year":"2024","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib5","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/cas.16097","article-title":"Beyond blood: advancing the frontiers of liquid biopsy in oncology and personalized medicine","volume":"115","author":"Bao","year":"2024","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2026.105661_bib6","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib7","doi-asserted-by":"crossref","first-page":"8512","DOI":"10.1200\/JCO.2025.43.16_suppl.8512","article-title":"Telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced EGFR-mutated (MT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase 1 study","volume":"43","author":"Camidge","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103083","article-title":"Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?","volume":"143","author":"Cheo","year":"2026","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105661_bib9","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105661_bib10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jtho.2022.11.022","article-title":"Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-Mutant Lung Cancers","volume":"18","author":"Choudhury","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib11","unstructured":"ClinicalTrials.gov, 2025a. A study of BL-B01D1 in combination with osimertinib versus osimertinib as first-line treatment in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer(PANKU-Lung04). NCT06838273. https:\/\/clinicaltrials.gov\/study\/NCT06838273."},{"key":"10.1016\/j.critrevonc.2026.105661_bib12","unstructured":"ClinicalTrials.gov, 2025b. A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC. NCT07183189. https:\/\/clinicaltrials.gov\/study\/NCT07183189."},{"key":"10.1016\/j.critrevonc.2026.105661_bib13","unstructured":"ClinicalTrials.gov, 2026. Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01). NCT07100080. https:\/\/clinicaltrials.gov\/study\/NCT07100080."},{"key":"10.1016\/j.critrevonc.2026.105661_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.108066","article-title":"Antibody-drug conjugates: a new twist to overcome EGFR-TKIs resistance in non-small cell lung cancer","volume":"223","author":"Deng","year":"2026","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.critrevonc.2026.105661_bib15","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1158\/1078-0432.CCR-24-0466","article-title":"Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling","volume":"30","author":"El Zarif","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105661_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-085680","article-title":"Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial","volume":"389","author":"Fang","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2026.105661_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa2512071","article-title":"Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC","volume":"394","author":"Fang","year":"2026","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105661_bib18","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.015","article-title":"PL02.11 Normalized Membrane Ratio of TROP2 by Quantitative Continuous Scoring is Predictive of Clinical Outcomes in TROPION-Lung 01","volume":"19","author":"Garassino","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyag285","article-title":"EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the \"Rebiopsy on Osi\" study)","volume":"31","author":"Gariazzo","year":"2026","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2026.105661_bib20","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/1535-7163.MCT-23-0784","article-title":"MYTX-011: a pH-Dependent Anti-c-MET Antibody-Drug Conjugate Designed for Enhanced Payload Delivery to c-MET-Expressing Tumor Cells","volume":"23","author":"Gera","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105661_bib21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/0008-5472.CAN-21-2426","article-title":"EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd","volume":"82","author":"Haikala","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105661_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108425","article-title":"Evaluating the safety of antibody-drug conjugates in lung cancer: a systematic review and meta-analysis","volume":"201","author":"He","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105661_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2026.109507","article-title":"New biomarkers for antibody-drug conjugates in lung cancer the pathologist's perspective","volume":"218","author":"Hofman","year":"2026","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105661_bib24","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.annonc.2026.01.009","article-title":"Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials","volume":"37","author":"Hong","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib25","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.annonc.2025.01.001","article-title":"Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced\/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib","volume":"36","author":"Horinouchi","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib26","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.jtho.2025.07.129","article-title":"Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC","volume":"20","author":"J\u00e4nne","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib27","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.43107","article-title":"Trastuzumab deruxtecan for ERBB2-mutant metastatic non-small cell lung cancer with or without brain metastases: a secondary analysis of randomized clinical trials","volume":"8","author":"J\u00e4nne","year":"2025","journal-title":"JAMA Netw. Open."},{"key":"10.1016\/j.critrevonc.2026.105661_bib28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1056\/NEJMoa2510308","article-title":"Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC","volume":"394","author":"J\u00e4nne","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105661_bib29","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1200\/JCO.23.01435","article-title":"Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline","volume":"41","author":"Khurshid","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.106027","article-title":"Treatment options and considerations for acquired resistance in EGFR mutation-positive non-small-cell lung cancer","volume":"11","author":"Le","year":"2026","journal-title":"ESMO Open."},{"key":"10.1016\/j.critrevonc.2026.105661_bib31","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","article-title":"EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours","volume":"32","author":"Le Rhun","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101624","article-title":"Leptomeningeal metastasis from solid tumours: EANO-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"8","author":"Le Rhun","year":"2023","journal-title":"ESMO Open."},{"key":"10.1016\/j.critrevonc.2026.105661_bib33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105661_bib34","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.ccell.2026.05.020","article-title":"Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer","volume":"44","author":"Liao","year":"2026","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105661_bib35","doi-asserted-by":"crossref","first-page":"8593","DOI":"10.1200\/JCO.2024.42.16_suppl.8593","article-title":"Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced\/metastatic non-small cell lung cancer (a\/m NSCLC) with actionable genomic alterations (AGA): results from TROPION-Lung05","volume":"42","author":"Lisberg","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib36","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.2025.43.16_suppl.3000","article-title":"DB-1310, a HER3-targeted ADC, in pts with advanced solid tumors: preliminary results from the phase 1\/2a trial","volume":"43","author":"Lisberg","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib37","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.annonc.2024.08.2243","article-title":"Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study","volume":"35","author":"Lu","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib38","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105661_bib39","doi-asserted-by":"crossref","DOI":"10.1177\/17588359261430561","article-title":"TROPION-Lung14 study protocol: a phase III study of osimertinib in combination with datopotamab deruxtecan versus osimertinib alone as first-line treatment for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer","volume":"18","author":"Lu","year":"2026","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib40","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/cpt.70350","article-title":"Payload-based clinical pharmacology review of approved antibody-drug conjugates: commonalities and considerations for streamlined development","volume":"120","author":"Lu","year":"2026","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105661_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218622","article-title":"From linker stability to linker fitness: redefining ADC design for clinical translation","volume":"656","author":"Ma","year":"2026","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105661_bib42","article-title":"Efficacy and safety of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor resistance: a systematic review and meta-analysis","volume":"16","author":"Ma","year":"2026","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib43","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib44","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41571-023-00756-z","article-title":"Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours","volume":"20","author":"Mair","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib45","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.cell.2020.07.017","article-title":"Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing","volume":"182","author":"Maynard","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105661_bib46","unstructured":"Merck, 2025. Patritumab Deruxtecan Biologics License Application for Patients With Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn. https:\/\/www.merck.com\/news\/patritumab-deruxtecan-biologics-license-application-for-patients-with-previously-treated-locally-advanced-or-metastatic-egfr-mutated-non-small-cell-lung-cancer-voluntarily-withdrawn\/."},{"key":"10.1016\/j.critrevonc.2026.105661_bib47","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2025.43.16_suppl.8506","article-title":"Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study","volume":"43","author":"Mok","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102902","article-title":"Antibody-drug conjugates in NSCLC with actionable genomic alterations: optimizing smart delivery of chemotherapy to the target","volume":"134","author":"Mountzios","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105661_bib49","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cllc.2021.08.012","article-title":"The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer","volume":"23","author":"Nagasaka","year":"2022","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105661_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107385","article-title":"Management of HER2 alterations in non-small cell lung cancer - The past, present, and future","volume":"186","author":"N\u00fctzinger","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105661_bib51","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jtho.2023.12.019","article-title":"Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC","volume":"19","author":"Odintsov","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib52","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","article-title":"Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes","volume":"14","author":"Offin","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib53","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41571-024-00970-3","article-title":"Leptomeningeal metastatic disease: new frontiers and future directions","volume":"22","author":"Ozair","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib54","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41571-023-00808-4","article-title":"Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer","volume":"20","author":"Pan","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib55","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1200\/JCO.23.00013","article-title":"Antibody-drug conjugates in lung cancer: recent advances and implementing strategies","volume":"41","author":"Passaro","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib56","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.annonc.2022.02.003","article-title":"ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer","volume":"33","author":"Passaro","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib57","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib58","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib59","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-25-0960","article-title":"ELIOS: a multicenter, molecular profiling study of patients with EGFR-mutant advanced non-small cell lung cancer treated with first-line osimertinib","volume":"16","author":"Piotrowska","year":"2026","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105661_bib60","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jtho.2025.09.061","article-title":"OA10.01 Intracranial Efficacy of Datopotamab Deruxtecan (Dato-DXd) in Patients With Advanced\/Metastatic NSCLC in TROPION-Lung01","volume":"20","author":"Pons-Tostivint","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open."},{"key":"10.1016\/j.critrevonc.2026.105661_bib62","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jtho.2022.10.015","article-title":"MET alterations in NSCLC-Current Perspectives and Future Challenges","volume":"18","author":"Remon","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib63","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib64","first-page":"e89","article-title":"Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1","volume":"44","author":"Reuss","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib65","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.annonc.2026.02.014","article-title":"Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD","volume":"37","author":"Riess","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib66","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.16_suppl.TPS8661","article-title":"AndroMETa-Lung-713: A phase 2\/3 study of telisotuzumab adizutecan (ABBV-400, Temab-A) vs standard of care (SOC) in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC)","volume":"44","author":"Rock","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib67","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid Biopsy for Advanced NSCLC: a consensus statement from the international association for the study of lung cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib68","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO-24-01349","article-title":"Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study","volume":"43","author":"Sands","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.106349","article-title":"42P TROP2 normalised membrane ratio (NMR) assessed by quantitative continuous scoring (QCS): association with clinical outcomes with datopotamab deruxtecan (Dato-DXd) \u00b1 osimertinib (osi) in EGFR-mutated (EGFRm) NSCLC","volume":"11","author":"Sands","year":"2026","journal-title":"ESMO Open."},{"key":"10.1016\/j.critrevonc.2026.105661_bib70","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1158\/1078-0432.CCR-19-3563","article-title":"Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105661_bib71","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41392-025-02481-8","article-title":"A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib","volume":"10","author":"Shi","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105661_bib72","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1038\/s41467-025-59623-3","article-title":"Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinoma","volume":"16","author":"Shinozaki","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105661_bib73","unstructured":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., 2025. Third Indication for Kelun-Biotech\u2019s TROP2 ADC Sac-TMT Approved for Marketing by NMPA in EGFRm NSCLC Following Progression on EGFR-TKI Therapy. Available at: https:\/\/www.hkexnews.hk\/listedco\/listconews\/sehk\/2025\/1012\/2025101200012_c.pdf (accessed August 10, 2026)."},{"key":"10.1016\/j.critrevonc.2026.105661_bib74","doi-asserted-by":"crossref","unstructured":"Spira, A., Chae, Y., Gregorc, V., et al., 2026. Phase 1 global study of iza-bren in patients with metastatic EGFR-mutated NSCLC: results of the randomized dose expansion cohort. Presented at the IASLC 2026 World Conference on Lung Cancer, Seoul, Republic of Korea, September 12\u201315, 2026. Abstract OA10.01.","DOI":"10.1016\/j.jtho.2026.104239"},{"key":"10.1016\/j.critrevonc.2026.105661_bib75","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251385410","volume":"17","author":"Tan","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib76","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood-brain barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.critrevonc.2026.105661_bib77","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1158\/1078-0432.CCR-24-3347","article-title":"Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-type Non-Small Cell Lung Cancer","volume":"31","author":"Trontzas","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105661_bib78","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41698-025-01144-9","article-title":"MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer","volume":"9","author":"Tsao","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib79","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105661_bib80","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib81","unstructured":"U.S. Food and Drug Administration, 2025a. FDA grants accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated non-small cell lung cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer (accessed 10 August 2026)."},{"key":"10.1016\/j.critrevonc.2026.105661_bib82","unstructured":"U.S. Food and Drug Administration, 2025b. FDA grants accelerated approval to telisotuzumab vedotin-tllv for NSCLC with high c-Met protein overexpression. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-telisotuzumab-vedotin-tllv-nsclc-high-c-met-protein-overexpression (accessed 10 August 2026)."},{"key":"10.1016\/j.critrevonc.2026.105661_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103044","article-title":"Transformation from EGFR-mutant lung adenocarcinoma to small-cell lung cancer: from clonal evolution to lineage reprogramming","volume":"141","author":"Wang","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105661_bib84","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cllc.2025.11.015","article-title":"A Comprehensive Analysis of HER2 status Heterogeneity Using Matched Samples among Potential Beneficiaries of Trastuzumab Deruxtecan Therapy in Non-Small Cell Lung Cancer","volume":"27","author":"Wang","year":"2026","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105661_bib85","doi-asserted-by":"crossref","DOI":"10.1093\/nsr\/nwae392","article-title":"Integrative study of lung cancer adeno-to-squamous transition in EGFR TKI resistance identifies RAPGEF3 as a therapeutic target","volume":"11","author":"Wang","year":"2024","journal-title":"Natl. Sci. Rev."},{"key":"10.1016\/j.critrevonc.2026.105661_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2026.108914","article-title":"Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and network meta-analysis","volume":"212","author":"Wang","year":"2026","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105661_bib87","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/JTO.0b013e3182745948","article-title":"Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer","volume":"7","author":"Weickhardt","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib88","doi-asserted-by":"crossref","DOI":"10.1177\/17588359261469539","article-title":"Consensus recommendations for the management of Dato-DXd-associated adverse events in patients with advanced\/metastatic NSCLC: insights from a multiregional steering committee","volume":"18","author":"William","year":"2026","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.106317","article-title":"10MO SHR-A2009, a HER3-targeted ADC, plus aumolertinib (A) as 1L or \u22652L treatment for EGFR-mutated (EGFRm) NSCLC: A phase Ib\/II study","volume":"11","author":"Wu","year":"2026","journal-title":"ESMO Open."},{"key":"10.1016\/j.critrevonc.2026.105661_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108593","article-title":"Genomic profiling and prognostic factors of leptomeningeal metastasis in EGFR-mutant NSCLC after resistant to third-generation EGFR-tyrosine kinase inhibitors","volume":"205","author":"Xie","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105661_bib91","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study","volume":"38","author":"Yang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib92","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105661_bib93","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2026.114747","article-title":"The emerging role of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer with acquired resistance to third-generation EGFR tyrosine kinase inhibitors","volume":"393","author":"Zhang","year":"2026","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2026.105661_bib95","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41571-025-01085-z","article-title":"Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC - mechanisms and evolving treatment approaches","volume":"23","author":"Zhao","year":"2026","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib96","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","article-title":"The changing treatment landscape of EGFR-mutant non-small-cell lung cancer","volume":"22","author":"Zhou","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib97","first-page":"S32","article-title":"OA10.04 Phase II Study of Iza-Bren (BL-B01D1) Combo With Osimertinib in EGFR Mutated Locally Advanced or Metastatic NSCLC Patients","volume":"20","author":"Zhou","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib98","doi-asserted-by":"crossref","first-page":"S509","DOI":"10.1016\/j.annonc.2024.08.709","article-title":"642P Phase I study of SHR-A2009, a HER3-targeted ADC, in pretreated EGFR-mutated NSCLC","volume":"35","author":"Zhou","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105661_bib99","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41568-025-00869-w","article-title":"Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment","volume":"25","author":"Zippelius","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105661_bib100","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s40265-026-02331-z","article-title":"Antibody-drug conjugates in non-small cell lung cancer","volume":"86","author":"Zullo","year":"2026","journal-title":"Drugs"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T08:36:06Z","timestamp":1793003766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826005482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":100,"alternative-id":["S1040842826005482"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105661","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody\u2013drug conjugates after EGFR-TKI resistance in EGFR-mutant NSCLC: Evidence boundaries, post-progression reassessment, and therapeutic sequencing","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105661","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105661"}}